

## WEST Search History





DATE: Sunday, February 08, 2004

| <b>Hide?</b>             | <b>Set Name</b>                | <b>Query</b>  | <b>Hit Count</b> |
|--------------------------|--------------------------------|---|------------------|
|                          | <i>DB=USPT; PLUR=NO; OP=OR</i> |   |                  |
| <input type="checkbox"/> | L35                            | L34 and (mmp)   | 1                |
| <input type="checkbox"/> | L34                            | l28 and (lysozyme)                                    | 27               |
| <input type="checkbox"/> | L33                            | L28 and (mmp adj 1)                                   | 2                |
| <input type="checkbox"/> | L32                            | L28 and (mmp adj 12)                                  | 0                |
| <input type="checkbox"/> | L31                            | L28 and (mmp adj 12)                                  | 0                |
| <input type="checkbox"/> | L30                            | L28 and l10   | 0                |
| <input type="checkbox"/> | L29                            | L28 and l6  | 0                |
| <input type="checkbox"/> | L28                            | L27 and l24   | 116              |
| <input type="checkbox"/> | L27                            | l20 and l3  | 296              |
| <input type="checkbox"/> | L26                            | l20 and l2  | 0                |
| <input type="checkbox"/> | L25                            | l14 and l20   | 0                |
| <input type="checkbox"/> | L24                            | l20 and l1  | 652              |
| <input type="checkbox"/> | L23                            | L22 l20 and l1  | 656              |
| <input type="checkbox"/> | L22                            | L20 and (l11 or l10 or l9 or l7)                      | 4                |
| <input type="checkbox"/> | L21                            | L20 and (l11 or l10 or l9 or l7 or l1 or l2 or l3)    | 836              |
| <input type="checkbox"/> | L20                            | (inflammatory adj bowel adj disease) or ibd           | 4893             |
| <input type="checkbox"/> | L19                            | L11 and l10 and l9 and l7                             | 0                |
| <input type="checkbox"/> | L18                            | L11 and l10   | 0                |
| <input type="checkbox"/> | L17                            | L16 and l6  | 0                |
| <input type="checkbox"/> | L16                            | l14 and l3  | 1                |
| <input type="checkbox"/> | L15                            | L14 and l2  | 0                |
| <input type="checkbox"/> | L14                            | l11 and l1  | 1                |
| <input type="checkbox"/> | L13                            | L11 and l10   | 0                |
| <input type="checkbox"/> | L12                            | L11 and l10 and l9 and l7 and l6                      | 0                |
| <input type="checkbox"/> | L11                            | (max adj interacting adj protein adj 1) or mxii       | 9                |
| <input type="checkbox"/> | L10                            | (down adj regulated adj in adj rhabdosarcoma) or dral | 115              |
| <input type="checkbox"/> | L9                             | calgizzarin   | 9                |
| <input type="checkbox"/> | L8                             | calgizzatin   | 0                |
| <input type="checkbox"/> | L7                             | dd96  | 4                |
| <input type="checkbox"/> | L6                             | dra or (down adj regulated adj adenoma)               | 913              |
| <input type="checkbox"/> | L5                             | gos2  | 16               |

|                          |    |   |      |
|--------------------------|----|---|------|
| <input type="checkbox"/> | L4 | (phospholipase adj a2 adj group adj iia) or pla2g2a | 8    |
| <input type="checkbox"/> | L3 | metallothionein                                     | 5003 |
| <input type="checkbox"/> | L2 | (growth adj hormone adj 2) or gh2                   | 139  |
| <input type="checkbox"/> | L1 | (il adj 8) or mdncf                                 | 2299 |

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 11:15:17 ON 08 FEB 2004)

FILE 'MEDLINE, SCISEARCH' ENTERED AT 11:16:02 ON 08 FEB 2004

FILE 'MEDLINE, CAPLUS, SCISEARCH' ENTERED AT 11:16:26 ON 08 FEB 2004

|     |  |
|-----|--|
| L1  | 28428 S INFLAMMATORY BOWEL DISEASE                         |
| L2  | 30656 S L1 OR IBD  |
| L3  | 16 S L2 AND IL8  |
| L4  | 2823 S IP-10   |
| L5  | 544 S (GROWTH HORMONE 2) OR GH2                            |
| L6  | 108 S GRO1   |
| L7  | 32 S GRO2  |
| L8  | 432 S (NEUTROPHIL LIPOCALIN) OR HNL                        |
| L9  | 23714 S METALLOTHIONEIN                                    |
| L10 | 36 S DD96 OR (EPITHELIAL PROTEIN UPREGULATED IN CARCINOMA) |
| L11 | 92 S CALGIZZARIN   |
| L12 | 156 S DRAL OR (DOWN REGULATED IN RHABDOSARCOMA)            |
| L13 | 12 S MAX INTERACTING PROTEIN 1                             |
| L14 | 0 S L2 AND L13 AND L12 AND L11 AND L10 AND L9              |
| L15 | 1 S L2 AND L13   |

FILE 'STNGUIDE' ENTERED AT 11:23:05 ON 08 FEB 2004

FILE 'MEDLINE, SCISEARCH, CAPLUS' ENTERED AT 11:26:31 ON 08 FEB 2004

|     |                         |
|-----|-------------------------|
| L16 | 5 S L2 AND L12          |
| L17 | 19 S L2 AND L4          |
| L18 | 0 S L17 AND L9          |
| L19 | 1 S L17 AND L5          |
| L20 | 1 S L17 AND IL8         |
| L21 | 29 S L2 AND IL6         |
| L22 | 0 S L21 AND L9          |
| L23 | 2 S L21 AND MMP         |
| L24 | 49 S L2 AND MICROARRAY# |

FILE 'GENBANK' ENTERED AT 11:40:21 ON 08 FEB 2004

|     |              |
|-----|--------------|
| L25 | 2 S Y00787   |
| L26 | 34 S X54489  |
| L27 | 2 S M57731   |
| L28 | 2 S M28130   |
| L29 | 36 S J03756  |
| L30 | 1 S S75256   |
| L31 | 2 S X99133   |
| L32 | 1 S X85781   |
| L33 | 3 S X65965   |
| L34 | 114 S M22430 |
| L35 | 1 S X51441   |
| L36 | 1 S J03474   |
| L37 | 9 S M21119   |
| L38 | 53 S D00408  |
| L39 | 46 S D14662  |

FILE 'CAPLUS' ENTERED AT 11:43:49 ON 08 FEB 2004

|     |   |
|-----|---|
| L40 | 0 S L39 AND L38 AND L37 AND L36 AND L35 AND L34 |
| L41 | 0 S L39 AND L38 AND L37 AND L36 AND L35         |
| L42 | 0 S L39 AND L38 AND L37 AND L36                 |
| L43 | 0 S L39 AND L38 AND L37                         |
| L44 | 0 S L39 AND L38 AND L37 AND (L36 OR L35 OR L34) |
| L45 | 0 S L39 AND L38 AND (L37 OR L36 OR L35 OR L34)  |
| L46 | 9 S L39   |
| L47 | 1 S L46 AND L2                                  |
| L48 | 0 S L38 AND L2                                  |

|     |                         |
|-----|-------------------------|
| L49 | 0 S L37 AND L2          |
| L50 | 0 S L37 AND L2          |
| L51 | 0 S L36 AND L2          |
| L52 | 0 S L35 AND L2          |
| L53 | 0 S L34 AND L2          |
| L54 | 0 S L33 AND L2          |
| L55 | 0 S L25 AND L2          |
| L56 | 0 S L26 AND L2          |
| L57 | 0 S L27 AND L2          |
| L58 | 1 S L28 AND L2          |
| L59 | 0 S L29 AND L2          |
| L60 | 0 S L30 AND L2          |
| L61 | 0 S L31 AND L2          |
| L62 | 0 S L31 AND L2          |
| L63 | 0 S L33 AND L2          |
|     | E LAWRENCE IAN C/AU     |
|     | E FIOCCHI CLAUDIO/AU    |
| L64 | 6 S E1                  |
| L65 | 50 S E3                 |
| L66 | 0 S L64 AND L65         |
| L67 | 56 S L64 OR L65         |
| L68 | 34 S L67 AND L2         |
| L69 | 1 S L68 AND MICROARRAY# |
| L70 | 1 S L69                 |
| L71 | 1 S L68 AND HNL         |
| L72 | 1 S NGAL AND L68        |
|     | E LAWRENCE IAN C/AU     |
| L73 | 2 S E3                  |
|     | E CHAKRAVARTI SHUKTI/AU |
| L74 | 4 S E3 AND L2           |

=>

L68 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1996:521277 CAPLUS  
 DN 125:192733  
 ED Entered STN: 30 Aug 1996  
 TI Interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**  
 AU Matsuura, Toshihiro; Kusugami, Kazuo; Morise, Kimitomo; **Fiocchi, Claudio**  
 CS 1st Dep. Internal Med., Nagoya Univ. Sch. Med., Nagoya, Japan  
 SO Cytokines in Inflammatory Bowel Disease (1996), 41-56. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.  
 CODEN: 63GUAH  
 DT Conference; General Review  
 LA English  
 CC 15-0 (Immunochemistry)  
 AB A review, with 98 refs. The authors discuss interleukin-2 activity by intestinal mucosal mononuclear cells in **inflammatory bowel disease (IBD)**, soluble interleukin-2 receptor production by lamina propria mononuclear cells, lymphokine-activated killer cell activity in **IBD**, and levels of IL-2 and IL-2R mRNA in **IBD**.  
 ST review interleukin 2 **inflammatory bowel disease**  
 IT Intestine, disease  
 (inflammatory, interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**)  
 IT Lymphokines and Cytokines  
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (interleukin 2, interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**)  
 IT Lymphokine and cytokine receptors  
 Receptors  
 RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence)  
 (interleukin 2, interleukin-2 and interleukin-2 receptor in **inflammatory bowel disease**)

L68 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1996:521279 CAPLUS  
 DN 125:192735  
 ED Entered STN: 30 Aug 1996  
 TI Interleukin-6 in **inflammatory bowel disease**  
 AU Kusugami, Kazuo; Morise, Kimitomo; Shinoda, Masataka; Haruta, Jun-ichi; Tanimoto, Mitsune  
 CS 1st Dep. Internal Med., Nagoya Univ. Sch. Med., Nagoya, Japan  
 SO Cytokines in Inflammatory Bowel Disease (1996), 69-83. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.  
 CODEN: 63GUAH  
 DT Conference; General Review  
 LA English  
 CC 15-0 (Immunochemistry)  
 AB A review, with 89 refs. Based on the multitude of biol. functions of IL-6 on essentially all tissues and cells in the body, this cytokine has also attracted much attention in the pathogenesis of **inflammatory bowel disease (IBD)** under the assumption that dysregulation of IL-6 activity may be associated with immune abnormalities in patients with ulcerative colitis and Crohn's disease. This paper discusses IL-6 in **IBD**, keeping in mind that the investigation of

IL-6 in **IBD** patients to clarify its involvement in the pathogenesis and perpetuation of **IBD** is still in progress.

ST review interleukin 6 **inflammatory bowel disease**

IT Intestine, disease  
(inflammatory, interleukin-6 in **inflammatory bowel disease**)

IT Lymphokines and Cytokines  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(interleukin 6, interleukin-6 in **inflammatory bowel disease**)

L68 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1996:521281 CAPLUS  
DN 125:192737  
ED Entered STN: 30 Aug 1996  
TI Chemotactic cytokines (chemokines) in **inflammatory bowel disease**

AU MacDermott, Richard P.; Izutani, Ryo; Ohno, Yasuhiro; Reinecker, Hans-Christian

CS Gastroenterology Section, Lahey Clinic, Burlington, MA, USA

SO Cytokines in Inflammatory Bowel Disease (1996), 101-118. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.  
CODEN: 63GUAH

DT Conference; General Review

LA English

CC 15-0 (Immunochemistry)

AB A review with 102 refs. The presence of large nos. of granulocytes and macrophages in the bowel wall is a common feature in **inflammatory bowel disease (IBD)**. Granulocytes and macrophages are thought to contribute to the immunopathogenesis of **IBD**. The constant flux of granulocytes and macrophages indicates the likely presence of potent chemotactic agents in inflamed intestinal mucosa. The regulation of granulocyte and macrophage movement into inflamed mucosal and submucosal tissue may also be mediated by chemokines, which are potent mediators of granulocyte and macrophage migration and activation. Two of the chemokines, interleukin-8 and monocyte chemotactic and activating factor (MCAF) are likely to have important roles in mediating chronic intestinal inflammation in diseases such as **IBD**

ST review chemokine **inflammatory bowel disease**

IT Lymphokines and Cytokines  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(chemokines, chemotactic cytokines (chemokines) in **inflammatory bowel disease**)

IT Intestine, disease  
(inflammatory, chemotactic cytokines (chemokines) in **inflammatory bowel disease**)

L68 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1996:521282 CAPLUS  
DN 125:192738  
ED Entered STN: 30 Aug 1996  
TI The colony-stimulating factors in **inflammatory bowel disease**

AU Doe, William F.; Grimm, Michael C.

CS John Curtin Sch. Clinical Res., Australian natl. Univ., Canberra City, Australia

SO Cytokines in Inflammatory Bowel Disease (1996), 119-136. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.  
CODEN: 63GUAH

DT Conference; General Review

LA English  
 CC 15-0 (Immunochemistry)  
 AB A review, with 65 refs. The authors discuss the biol. activities of each of the colony-stimulating factors (CSFs), their potential roles and synergies in immune and inflammatory responses and the potential effects of these functions on the regulation and mediation of mucosal inflammation in **inflammatory bowel disease (IBD)** ).  
 ST review colony stimulating factor bowel disease  
 IT Intestine, disease  
 (inflammatory, colony-stimulating factors in **inflammatory bowel disease**)  
 IT 62683-29-8, Colony-stimulating factor  
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
 (colony-stimulating factors in **inflammatory bowel disease**)

L68 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1996:521283 CAPLUS  
 DN 125:192063  
 ED Entered STN: 30 Aug 1996  
 TI Peptide growth factors in **inflammatory bowel disease**  
 AU Dignass, Axel U.; Podolsky, Daniel K.  
 CS Dep. Med., Univ. Essen, Essen, Germany  
 SO Cytokines in Inflammatory Bowel Disease (1996), 137-155. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex.  
 CODEN: 63GUAH  
 DT Conference; General Review  
 LA English  
 CC 14-0 (Mammalian Pathological Biochemistry)  
 AB A review, with 76 refs., of general properties of prototypic peptide growth factors which are likely to be important in **inflammatory bowel disease** including EGF, TGF- $\alpha$ , TGF- $\beta$ , IGF, FGF, HGF, CSF, and trefoil factors.  
 ST review growth factor **inflammatory bowel disease**  
 IT Animal growth regulators  
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
 (peptide growth factors in **inflammatory bowel disease**)  
 IT Intestine, disease  
 (inflammatory, peptide growth factors in **inflammatory bowel disease**)

L68 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1996:547943 CAPLUS  
 DN 125:219585  
 ED Entered STN: 13 Sep 1996  
 TI Cytokines in **Inflammatory Bowel Disease**.  
 AU **Fiocchi, Claudio**; Editor  
 CS USA  
 SO (1996) Publisher: (Landes, Austin, Tex.), 265 pp.  
 DT Book  
 LA English  
 CC 15-8 (Immunochemistry)  
 Section cross-reference(s): 14  
 AB Unavailable  
 ST book cytokine **inflammatory bowel disease**  
 IT Lymphokines and Cytokines  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(cytokines in **inflammatory bowel disease**)

IT Intestine, disease  
(inflammatory, cytokines in **inflammatory bowel disease**)

L68 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:521276 CAPLUS

DN 125:192732

ED Entered STN: 30 Aug 1996

TI Interleukin-1 and interleukin-1 receptor antagonist in **inflammatory bowel disease**

AU Kam, Lori; Cominelli, Fabio

CS Div. Gastrointestinal Liver Diseases, Univ. Southern California Sch. Med., Los Angeles, CA, USA

SO Cytokines in Inflammatory Bowel Disease (1996), 27-39. Editor(s): **Fiocchi, Claudio**. Publisher: Landes, Austin, Tex. CODEN: 63GUAH

DT Conference; General Review

LA English

CC 15-0 (Immunochemistry)

AB A review, with 36 refs. Immune cells and their cytokines are likely to play an important role in the initiation and perpetuation of the chronic inflammation associated with ulcerative colitis and Crohn's disease. Activated mononuclear cells produce interleukin-1 (IL-1), a pro-inflammatory cytokine with multiple biol. properties that may be responsible for the initiation and amplification of the inflammatory response. Macrophage activation has been hypothesized to be an early event in the pathogenesis of intestinal bowel disease (**IBD**). This suggests that IL-1 is also involved in the early events of the inflammatory cascade. This paper reviews the role of IL-1 and IL-1ra in **IBD**, and discusses new strategies for treatment of **IBD** based on the modulation of IL-1 activity.

ST review interleukin 1 **inflammatory bowel disease**

IT Intestine, disease  
(inflammatory, interleukin-1 and interleukin-1 receptor antagonist in **inflammatory bowel disease**)

IT Lymphokines and Cytokines  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(interleukin 1, interleukin-1 and interleukin-1 receptor antagonist in **inflammatory bowel disease**)

IT Lymphokines and Cytokines  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(interleukin 1 receptor antagonist, interleukin-1 and interleukin-1 receptor antagonist in **inflammatory bowel disease**)